Study guide

4.3 Renal and Hepatic Emergencies in Transport

IBSC CCP-C Certified Critical Care Paramedic Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 About the CCP-C Exam 1.2 CCP-C Study Strategy & Exam Tactics

2 Chapter 2: Transport and Safety (Part 1)

2.1 Crew Resource Management & Sterile Cockpit Rule 2.2 Transport Risk Assessment & Mission Decision-Making 2.3 Aircraft and Ground Transport Safety Protocols

3 Chapter 2: Transport and Safety (Part 2)

2.4 Environmental Transport Stressors & Gas Laws 2.5 Transport Equipment Management & Post-Mission Operations

4 Chapter 3: Airway, Anesthesia, and Analgesics (Part 1)

3.1 Advanced Airway Assessment & Difficult Airway Identification 3.2 Rapid Sequence Induction (RSI) - Pretreatment & Induction Agents 3.3 Neuromuscular Blockade - Depolarizing vs Non-Depolarizing Agents 3.4 Post-Intubation Sedation, Analgesia & Dissociative Maintenance 3.5 Transport Ventilator Setup & Primary Ventilation Modes

5 Chapter 3: Airway, Anesthesia, and Analgesics (Part 2)

3.6 Mechanical Ventilator Waveforms, Loops & Oxygenation Titration 3.7 Ventilator Alarm Troubleshooting & Peak vs Plateau Pressures 3.8 Rescue Airway Devices, Video Laryngoscopy & Surgical Cricothyrotomy 3.9 Neuromuscular Reversal & Vasoactive Airway Support 3.10 Transport Airway Management in Unique Environments & Extubation

6 Chapter 4: General Medical Patient

4.1 Sepsis, Severe Sepsis & Septic Shock Resuscitation 4.2 Endocrine Emergencies (DKA, HHS, Adrenal Crisis, Thyroid Storm) 4.3 Renal and Hepatic Emergencies in Transport

7 Chapter 5: Cardiac Patient

5.1 Acute Coronary Syndromes & Infarct Specific Complications 5.2 Invasive Hemodynamic Monitoring 5.3 Vasoactive & Inotropic Medication Titration 5.4 Mechanical Circulatory Support & Post-Cardiac Arrest Care

8 Chapter 6: Neurological Patient

6.1 Traumatic Brain Injury & Intracranial Pressure (ICP) Management 6.2 Acute Ischemic Stroke, Hemorrhagic Stroke & Subarachnoid Hemorrhage 6.3 Status Epilepticus, Spinal Cord Injury & Neurogenic Shock

9 Chapter 7: Respiratory Patient

7.1 Acute Respiratory Distress Syndrome (ARDS) & Lung-Protective Ventilation 7.2 Severe Asthma & COPD Exacerbations in Critical Care 7.3 Chest Tube Management, Pleural Drains & Tension Pneumothorax 7.4 Pulmonary Embolism, Pulmonary Hypertension & Transport Respiratory Meds

10 Chapter 8: Toxic Exposure and Environmental Patient

8.1 Toxicology Emergencies, Toxidromes & Antidote Therapy 8.2 Environmental Emergencies (Hypothermia, Hyperthermia, Frostbite) 8.3 Submersion, Diving Emergencies & Envenomation/HazMat

11 Chapter 9: Trauma and Burn Patient

9.1 Hemorrhagic Shock Resuscitation & Massive Transfusion Protocols (MTP) 9.2 Severe Thoracic & Abdominal Trauma Management 9.3 Thermal, Chemical & Electrical Burn Assessment & Fluid Resuscitation 9.4 Musculoskeletal Trauma, Pelvic Fractures & Compartment Syndrome

12 Chapter 10: Maternal and Fetal Medicine

10.1 High-Risk Obstetric Assessment & Hypertensive Disorders of Pregnancy 10.2 Obstetric Hemorrhage, Placental Abruption & Preterm Labor 10.3 Emergency Transport Delivery, Umbilical Cord Prolapse & Fetal Monitoring

13 Chapter 11: Pediatric Patient

11.1 Pediatric Critical Care Airway & Transport Ventilation 11.2 Pediatric Shock, Dehydration & Weight-Based Dosing 11.3 Neonatal Resuscitation Program (NRP) & Transport of the Critical Neonate

14 Chapter 12: Special Populations

12.1 Bariatric Critical Care Transport & Positional Management 12.2 Geriatric Critical Care & Patients with Specialized Medical Technology

15 Chapter 13: Professional Considerations

13.1 Legal Aspects, EMTALA & Transport Ethics 13.2 Quality Improvement, Transport Safety Research & Evidence-Based Practice

4.3 Renal and Hepatic Emergencies in Transport

Key Takeaways Explain This Topic AI

Acute Kidney Injury (AKI) is staged using RIFLE or KDIGO criteria, classifying dysfunction into prerenal hypoperfusion, intrinsic parenchymal injury, and postrenal obstruction.

Hyperkalemia emergency management follows a three-step timeline: immediate membrane stabilization with IV Calcium, intracellular shifting with Insulin/Dextrose and Albuterol, and ultimate elimination via loop diuretics, binders, or hemodialysis.

ESRD patients with AV fistulas or grafts require strict transport precautions: never measure blood pressure or perform venipuncture on the shunt arm, and routinely assess for thrill and bruit.

CRRT transport demands continuous circuit pressure monitoring, meticulous fluid balance management, and strict maintenance of double-lumen vascular access lines.

Hepatic encephalopathy treatment centers on Lactulose (trapping ammonia as non-absorbable ammonium) and Rifaximin; hepatorenal syndrome requires splanchnic vasoconstrictors (terlipressin/norepinephrine) combined with IV Albumin.

Last updated: July 2026

  • 4.3 Renal and Hepatic Emergencies in Transport
  • Acute Kidney Injury (AKI) Etiologies & Staging

Acute Kidney Injury ( AKI ) is characterized by a rapid decline in glomerular filtration rate (GFR), resulting in the accumulation of nitrogenous waste products (blood urea nitrogen [BUN] and serum creatinine) and dysregulation of fluid, electrolyte, and acid-base homeostasis.

Etiological Categories

Prerenal Azotemia : Caused by renal hypoperfusion without cellular parenchymal damage (e.g., severe hypovolemia, septic shock, heart failure, renal artery stenosis). Fractional excretion of sodium ( FENa \text{FENa} FENa ) is typically < 1 % < 1\% < 1% , and BUN : Creatinine \text{BUN}:\text{Creatinine} BUN : Creatinine ratio is > 20 : 1 > 20:1 > 20 : 1 .

Intrinsic / Intrarenal AKI : Caused by direct structural injury to the glomeruli, tubules, or interstitium. Acute Tubular Necrosis (ATN) from prolonged ischemia or nephrotoxins (aminoglycosides, iodinated contrast, rhabdomyolysis myoglobin) is the most common cause. FENa > 2 % \text{FENa} > 2\% FENa > 2% , BUN : Creatinine < 15 : 1 \text{BUN}:\text{Creatinine} < 15:1 BUN : Creatinine < 15 : 1 , with muddy brown granular casts in urine sediment.

Postrenal AKI : Caused by urinary tract obstruction downstream of the kidneys (e.g., bilateral ureteral obstruction, prostatic hypertrophy, neurogenic bladder, obstructed Foley catheter).

AKI Staging Criteria: RIFLE vs. KDIGO

Stage / Class RIFLE Criteria (Creatinine & GFR) RIFLE Urine Output KDIGO Staging (Creatinine) KDIGO Urine Output

Risk / Stage 1 ↑ \uparrow ↑ Serum Cr × 1.5 \times 1.5 × 1.5 or GFR ↓ > 25 % \downarrow > 25\% ↓> 25% < 0.5 mL/kg/hr × 6 hrs < 0.5\text{ mL/kg/hr} \times 6\text{ hrs} < 0.5 mL/kg/hr × 6 hrs ↑ \uparrow ↑ Cr × 1.5 − 1.9 \times 1.5 - 1.9 × 1.5 − 1.9 baseline or ≥ 0.3 mg/dL \ge 0.3\text{ mg/dL} ≥ 0.3 mg/dL rise < 0.5 mL/kg/hr × 6 − 12 hrs < 0.5\text{ mL/kg/hr} \times 6-12\text{ hrs} < 0.5 mL/kg/hr × 6 − 12 hrs

Injury / Stage 2 ↑ \uparrow ↑ Serum Cr × 2.0 \times 2.0 × 2.0 or GFR ↓ > 50 % \downarrow > 50\% ↓> 50% < 0.5 mL/kg/hr × 12 hrs < 0.5\text{ mL/kg/hr} \times 12\text{ hrs} < 0.5 mL/kg/hr × 12 hrs ↑ \uparrow ↑ Cr × 2.0 − 2.9 \times 2.0 - 2.9 × 2.0 − 2.9 baseline < 0.5 mL/kg/hr ≥ 12 hrs < 0.5\text{ mL/kg/hr} \ge 12\text{ hrs} < 0.5 mL/kg/hr ≥ 12 hrs

Failure / Stage 3 ↑ \uparrow ↑ Serum Cr × 3.0 \times 3.0 × 3.0 or GFR ↓ > 75 % \downarrow > 75\% ↓> 75% < 0.3 mL/kg/hr × 24 hrs < 0.3\text{ mL/kg/hr} \times 24\text{ hrs} < 0.3 mL/kg/hr × 24 hrs or Anuria × 12 hrs \times 12\text{ hrs} × 12 hrs ↑ \uparrow ↑ Cr × 3.0 \times 3.0 × 3.0 baseline or Cr ≥ 4.0 mg/dL \text{Cr} \ge 4.0\text{ mg/dL} Cr ≥ 4.0 mg/dL or RRT < 0.3 mL/kg/hr ≥ 24 hrs < 0.3\text{ mL/kg/hr} \ge 24\text{ hrs} < 0.3 mL/kg/hr ≥ 24 hrs or Anuria ≥ 12 hrs \ge 12\text{ hrs} ≥ 12 hrs

Loss Persistent complete loss of renal function > 4 weeks > 4\text{ weeks} > 4 weeks N/A Subsumed under Stage 3 N/A

  • ESRD End-Stage Renal Disease > 3 months > 3\text{ months} > 3 months N/A Subsumed under Stage 3 N/A
  • Emergency Hyperkalemia Management Protocol

Hyperkalemia ( [ K + ] > 5.0 mEq/L [\text{K}^+] > 5.0\text{ mEq/L} [ K + ] > 5.0 mEq/L ) is a life-threatening complication of renal failure. Severe hyperkalemia ( [ K + ] > 6.5 mEq/L [\text{K}^+] > 6.5\text{ mEq/L} [ K + ] > 6.5 mEq/L ) alters resting membrane potentials, risking lethal arrhythmias.

ECG Evolution in Hyperkalemia

5.5 − 6.0 mEq/L 5.5 - 6.0\text{ mEq/L} 5.5 − 6.0 mEq/L : Narrow, tall, peaked T waves.

6.0 − 7.0 mEq/L 6.0 - 7.0\text{ mEq/L} 6.0 − 7.0 mEq/L : PR interval prolongation, flattening of P waves, ST-segment depression.

7.0 − 8.0 mEq/L 7.0 - 8.0\text{ mEq/L} 7.0 − 8.0 mEq/L : QRS complex widening, loss of P waves.

> 8.0 mEq/L > 8.0\text{ mEq/L} > 8.0 mEq/L : QRS merges with T wave creating a classic sine-wave pattern , culminating in ventricular fibrillation or asystole.

Multi-Tiered Hyperkalemia Interventions

Phase & Action Medication Route & Dosage Mechanism of Action Onset & Duration

1. Membrane Stabilization (Immediate) Calcium Chloride (10%) or Calcium Gluconate (10%) CaCl: 5 − 10 mL 5-10\text{ mL} 5 − 10 mL ( 1 g 1\text{ g} 1 g ) IV over 2-5 min (central line); CaGluc: 15 − 30 mL 15-30\text{ mL} 15 − 30 mL ( 1.5 − 3 g 1.5-3\text{ g} 1.5 − 3 g ) IV Antagonizes cardiac cell membrane excitability; raises threshold potential Onset: 1-3 minutes ; Duration: 30-60 minutes

2. Intracellular K+ Shifting (Temporary) Regular Insulin + Dextrose ( D 50 W D_{50}W D 50 ​ W ) 10 units Regular Insulin IV push + 50 mL 50\text{ mL} 50 mL D 50 W D_{50}W D 50 ​ W ( 25 g 25\text{ g} 25 g ) IV Stimulates N a + / K + Na^+/K^+ N a + / K + ATPase, driving K + K^+ K + into cells Onset: 15-30 minutes ; Duration: 4-6 hours

2. Intracellular K+ Shifting (Temporary) Albuterol (Nebulized) 10 − 20 mg 10 - 20\text{ mg} 10 − 20 mg nebulized continuously over 15 min β 2 \beta_2 β 2 ​ -agonist stimulating intracellular K + K^+ K + shift Onset: 15-30 minutes ; Duration: 2 hours

2. Intracellular K+ Shifting (Temporary) Sodium Bicarbonate 50 mEq 50\text{ mEq} 50 mEq ( 1 amp 1\text{ amp} 1 amp ) IV slow push over 5 min Drives K + K^+ K + into cells via H + / K + \text{H}^+/K^+ H + / K + exchange (best in severe acidosis) Onset: 30-60 minutes ; Duration: 2 hours

3. Potassium Elimination (Definitive) Furosemide 40 − 80 mg 40 - 80\text{ mg} 40 − 80 mg IV push Inhibits NKCC2 co-transporter in loop of Henle; increases renal K + K^+ K + excretion Onset: 15-30 minutes ; Requires functioning kidneys

3. Potassium Elimination (Definitive) Hemodialysis Emergency dialysis session Direct clearance of extracellular K + K^+ K + from bloodstream Immediate during procedure; Definitive treatment

Transport Pearl : Calcium stabilizes the myocardium but does NOT reduce total serum potassium. Always follow calcium administration immediately with intracellular shifting agents (Insulin + Dextrose, Albuterol).

End-Stage Renal Disease (ESRD) & Vascular Access Precautions

Patients with ESRD rely on permanent vascular access for hemodialysis:

Arteriovenous (AV) Fistula : Surgical anastomosis connecting a native artery directly to a vein (e.g., radiocephalic). Preferred due to lower infection and thrombosis rates.

Arteriovenous (AV) Graft : Synthetic polytetrafluoroethylene (PTFE) conduit bridging an artery and vein.

Transport Management Precautions

Strict Arm Restrictions : NEVER obtain non-invasive blood pressure, perform venipuncture, or establish IV access in the extremity containing an AV fistula or graft. Pressure occlusion causes graft thrombosis or fistula rupture.

Vascular Access Assessment : Palpate for a continuous thrill (vibratory sensation) and auscultate for a continuous bruit (machinery murmur) every shift and post-transfer. Absence of thrill/bruit indicates access thrombosis.

Hemostasis Control : If an AV fistula ruptures or bleeds during transport, apply direct digital pressure immediately just proximal and distal to the bleeding site. Avoid circumferential tourniquets if possible, as they destroy the shunt.

Dialysis Disequilibrium Syndrome (DDS) : Occurs during or shortly after hemodialysis due to rapid removal of urea from the intravascular space, creating a concentration gradient that shifts water into brain tissue. Manifests as headache, nausea, muscle cramps, confusion, seizures, and increased ICP. Treat with hypertonic saline or mannitol.

Continuous Renal Replacement Therapy (CRRT) Considerations

Transporting critically ill patients maintained on Continuous Renal Replacement Therapy ( CRRT ) requires specialized vigilance:

Modalities : Continuous Venovenous Hemofiltration ( CVVH - convection), Continuous Venovenous Hemodialysis ( CVVHD - diffusion), and Continuous Venovenous Hemodiafiltration ( CVVHDF - combined).

Circuit Pressure Monitoring : Monitor Filter Pressure, Access (Arterial) Pressure, Return (Venous) Pressure, and Transmembrane Pressure (TMP). A rising TMP indicates impending filter clotting.

Dual-Lumen Catheter Maintenance : Large-bore hemodialysis catheters (VasCath/PermCath) placed in the internal jugular or femoral vein must NEVER be accessed for routine IV fluid or medication administration unless during cardiac arrest or explicit protocol clearance.

Hepatic Encephalopathy, Hyperammonemia & Hepatorenal Syndrome

Hepatic encephalopathy is a reversible neuropsychiatric syndrome complicating acute liver failure or advanced cirrhosis. It results from the liver's inability to metabolize nitrogenous toxins absorbed from the gut—principally ammonia ( N H 3 NH_3 N H 3 ​ ) .

Clinical Staging (West Haven Criteria)

Grade 1 : Euphoria or anxiety, mild confusion, impaired attention, slurred speech, subtle asterixis (flapping tremor).

Grade 2 : Lethargy, disorientation to time, inappropriate behavior, obvious asterixis.

Grade 3 : Somnolence to semi-stupor, responsive to verbal stimuli, profound confusion, gross disorientation.

Grade 4 : Coma (unresponsive to painful stimuli), decerebrate or decorticate posturing.

Pharmacological Management Protocol

Lactulose : Non-absorbable disaccharide administered 20 − 30 g 20 - 30\text{ g} 20 − 30 g PO/NG every 2-4 hours (or as a retention enema). Gut bacteria metabolize lactulose into lactic and acetic acids, acidifying the colonic lumen. Acidic pH converts gaseous ammonia ( N H 3 NH_3 N H 3 ​ ) into non-absorbable ammonium ( N H 4 + NH_4^+ N H 4 + ​ ), trapping it in the bowel. It also acts as an osmotic laxative to purge nitrogenous compounds. Target: 2-3 soft stools per day.

Rifaximin : Non-absorbable antibiotic ( 550 mg 550\text{ mg} 550 mg PO BID) that eradicates ammonia-producing colonic bacteria (e.g., E. coli ).

Cerebral Edema in Acute Liver Failure : Hyperammonemia causes astrocyte swelling and intracranial hypertension. Maintain head of bed at 30 ∘ 30^\circ 3 0 ∘ , maintain PaCO 2 \text{PaCO}_2 PaCO 2 ​ 35 − 40 mmHg 35-40\text{ mmHg} 35 − 40 mmHg , and infuse hypertonic saline to maintain target serum sodium 145 − 150 mEq/L 145-150\text{ mEq/L} 145 − 150 mEq/L .

Hepatorenal Syndrome (HRS)

Hepatorenal syndrome is functional renal failure occurring in severe liver disease caused by intense splanchnic arterial vasodilation, which leads to severe renal vasoconstriction and renal hypoperfusion.

Type 1 HRS : Rapidly progressive renal failure (doubling of baseline serum creatinine to > 2.5 mg/dL > 2.5\text{ mg/dL} > 2.5 mg/dL in < 2 weeks < 2\text{ weeks} < 2 weeks ). High mortality.

Management Strategy : Combine splanchnic vasoconstrictors ( Terlipressin , Norepinephrine , or Octreotide + Midodrine ) with continuous IV Albumin ( 1 g/kg 1\text{ g/kg} 1 g/kg on day 1, followed by 20 − 40 g/day 20-40\text{ g/day} 20 − 40 g/day ) to expand intravascular volume, increase mean arterial pressure, and reverse renal vasoconstriction.